The Shareholders Foundation announces that an investigation on behalf of investors of Horizon Pharma Inc (NASDAQ:HZNP) shares was launched over potential securities laws violations by Horizon Pharma and certain of its directors and officers.
Investors who purchased shares of Horizon Pharma Inc (NASDAQ:HZNP) have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Horizon Pharma Inc (NASDAQ:HZNP) concerning whether a series of statements by Horizon Pharma regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Horizon Pharma Inc reported that its annual Total Revenue rose from $18.84 million in 2012 to $74.02 million in 2013. Shares of Horizon Pharma Inc (NASDAQ:HZNP) grew from $2.14 per share in August 2013 to as high as $17.35 per share in March 2014.
Then on July 28, 2014, Horizon Pharma Inc (NASDAQ:HZNP) disclosed in a filing with the SEC that it has been verbally notified that in August 2014, two pharmacy benefit managers (“PBMs”), CVS Caremark (“Caremark”) and Express Scripts, Inc. (“ESI”), expect to announce DUEXIS ® and VIMOVO ® will no longer be on their formularies and will be placed on their exclusion lists effective January 1, 2015. Horizon Pharma Inc said that it expects to provide fiscal 2015 financial guidance in the fourth quarter, which will incorporate the effects, if any, of the potential actions by Caremark and ESI.
Shares of Horizon Pharma Inc (NASDAQ:HZNP) dropped from as high as $14.19 per share on July 25, 2014, to $9.06 per share during July 28, 2014.
On August 12, 2014, NASDAQ:HZNP shares closed at $9.37 per share.
Those who purchased shares of Horizon Pharma Inc (NASDAQ:HZNP) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego